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Summary A chelating derivative ofa-melanocyte stimulating hormone (MSH) has been synthesised, in which
two molecules of the hormone are cross-linked by diethylenetriamine pentaacetic acid (DTPA). This com-
pound, bisMSH-DTPA, was equipotent with MSH in an in vitro tyrosinase assay with Cloudman S91
melanoma cells. When DBA/2 mice bearing the same tumour were injected with bisMSH-DTPA labelled with
the 'y-emitting isotope indium-1Il ("'In), the radioactivity became rapidly associated with the melanoma
tissue. By 24 h post-injection, radioactivity in tumour tissue was significantly higher (P<0.001) than in spleen,
lung, brain, eye and skin. Uptake of radioactivity by the tumours was inhibited by a 200-fold molar excess of
MSH, whereas uptake by liver, kidney, spleen, lung, brain, eye and skin was unaffected. We conclude that
bisMSH-DTPA may offer an alternative to antibody targeting in the imaging of malignant melanoma.
Malignant melanoma is characterised by a tendency to meta-
stasise early and to be resistant to most conventional
therapies. The initial surgical management of the disease
would benefit if it were possible to discover whether metas-
tasis had taken place and to which locations. Although
radiolabelled antibodies and Fab fragments to several
tumour cell surface antigens have been used to image
melanomas successfully (Carrel et al., 1987; Eary et al.,
1989), their routine use for repetitive imaging has been
limited by concerns about their potential immunogenicity,
their specificity for the tumour and the reproducibility of
labelling (Larson et al., 1983; Schroff et al., 1985; Reckel,
1989). In the present paper, we suggest that some of these
limitations may be avoided by the use of imaging agents
derived from a-melanocyte stimulating hormone (MSH).
MSH is a 13-residue peptide whose sequence is conserved
in all mammals so far studied (Eberle, 1988). MSH mediates
a variety of neurophysiological effects (de Wied & Jolles,
1982), but its major function is the regulation of skin
pigmentation by the control of melanin synthesis and disper-
sal by melanocytes (Lerner & McGuire, 1961; Hruby et al.,
1984). Cell surface receptors for MSH are found on both
mouse (Siegrist et al., 1988) and human (Ghanem et al.,
1988; Tatro et al., 1990) malignant melanocytes and MSH
adducts have been used to target imaging (Bard et al., 1986)
and therapeutic (Liu et al., 1988) agents to melanoma cells in
culture.
The N-terminal residue in MSH is blocked by an acetyl
group, but this may be replaced by much larger substituents
such as fluorescein (Chaturvedi et al., 1985) or biotin
(Chaturvedi et al., 1984) with little or no effect on the
binding of the hormone to receptors. These observations led
us to investigate whether MSH with an N-terminal chelating
group might target radioactive isotopes to malignant
melanoma.
Materials and methods
Fmoc amino acid reagents for peptide synthesis were from
Novabiochem (UK) Ltd (Nottingham, UK) or from Milli-
Gen/Biosearch (Watford, UK). Other reagents were from
Fluka or Aldrich. Solvents were of analytical grade or were
redistilled before use. The bisMSH-DTPA used in most
experiments was custom synthesised by Cambridge Research
Biochemicals Ltd (Harston, UK). MSH was purchased from
Novabiochem (UK) Ltd. Indium-111 trichloride (specific
activity >0.37 MBq pg-' of indium) and L-3,5-3H-tyrosine
(2.15 TBq mmol-') were from Amersham International plc
(Amersham, UK). Chelex chelating resin was from BioRad
Laboratories Ltd (Watford, UK) and Detoxi-Gel mini-
columns were from Pierce Chemical Co. (Rockford, IL,
USA). DBA/2 mice were from a breeding colony maintained
at the Strangeways Research Laboratory. The in vivo work
was carried out under Home Office project licence no. PPL
70/00499.
Synthesis ofbisMSH-DTPA
Des-acetyl-MSH was synthesised step-wise from the C-term-
inus by the Fmoc-polyamide method (Atherton & Sheppard,
1989). Initial syntheses at the Strangeways Laboratory were
of low yield and a custom synthesis was performed by Cam-
bridge Research Biochemicals. In brief, the peptide was
assembled on Pepsyn K resin (2 g, capacity 0.1mmol g-')
using a benzhydrylamine linkage agent (Bernatowicz et al.,
1989). Fmoc amino acids were coupled as their pentafluoro-
phenyl or oxobenzotriazine esters in the presence of 1-
hydroxybenzotriazole (0.8 mmol of each). When assembly of
the peptide was complete, the N-terminal Fmoc group was
removed and the peptide-resin was treated with DTPA bis-
anhydride (0.3 mmol) and diisopropylethylamine (0.15
mmol). Reaction was complete in I h and the resin was
washed and dried. A portion of the resin (0.7 g) was treated
overnight with a mixture of- trifluoroacetic acid (TFA),
ethanedithiol, phenol and anisole (97:1:1:1, by volume).
Evaporation of the TFA solution and trituration with ether
yielded a white solid (110 mg). After isolation by preparative
reverse phase chromatography on Vydac 218TPB1520, the
product (11 mg) was shown to be homogeneous by analytical
HPLC. Its peptide structure was confirmed by amino acid
analysis and it was shown to be the bis-peptide adduct of
DTPA by fast-atom-bombardment mass spectrometry, which
gave a relative molecular mass of 3,602 ± 2.
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Figure I Structure of bisMSH-DTPA. MSH = -Ser-Tyr-Ser-
Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2.
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Binding of"'In to bisMSH-DTPA
A solution of bisMSH-DTPA (0.1 mgml-', 28 pM) was
prepared in sodium citrate buffer (0.1 M, pH 5.6) that had
been treated with Chelex resin to remove heavy metal con-
taminants and passed through a Detoxi-gel column to
remove pyrogens. To this solution was added carrier-free
"'InCl3 to a radiochemical concentration of 7.4MBqml1',
corresponding to a chemical concentration of less than
0.18tLM. Samples of this solution were maintained at 4°C,
20°C or 37°C and binding was assessed at 0, 15, 60, 120 and
270 min by thin layer chromatography (TLC) on silica gel,
using a solvent system consisting of 10% (w/v) ammonium
acetate in water/methanol, (1:1, v/v) (Frier & Hesselwood,
1980). BisMSH-DTPA-l'In had an Rf of 0.7, whereas
unbound indium remained at the origin. The stability of the
complex was checked by TLC after the fully complexed
bisMSH-DTPA-"'In had been allowed to stand for 0.5 h,
1.5 h, 5 h or 24 h at room temperature, with or without the
addition of human serum (50%, v/v). In some experiments,
the solvent mixture pyridine/acetic acid/butan-1-ol/water
(1:5:5:4, by volume) was used. In this system, "'In-labelled
bisMSH-DTPA migrates at the solvent front, whereas col-
loidal indium hydroxide migrates with an Rf of 0.6.
Assessment ofhormonal activity
In Cloudman S91 melanoma cells, MSH stimulates a dose-
dependent increase in the activity of tyrosinase (E.C.
1.14.18.1) (Pawelek et al., 1973), the rate limiting enzyme in
the melanin biosynthetic pathway. This assay was used to
assess the hormonal potency of bisMSH-DTPA. Cells were
grown in 25 cm2 flasks containing 4 ml of Ham's FlO
medium, supplemented with 10% heat-inactivated fetal calf
serum, to a density of 0.5- 1.0 x 104 cells cm-2 at 37°C in an
atmosphere of 5% CO2 in air. MSH or bisMSH-DTPA was
added and the cultures continued for 24 h. At this time the
medium was changed and fresh melanotropin was added,
together with 37 kBq of L-3,5-3H-tyrosine (4.3 nM). After a
further 24 h, the 3H-water in the medium was determined
(Lande et al., 1981). Results were corrected for variations in
cell number between flasks and expressed as a ratio over the
melanotropin-free result.
Tissue distribution in vivo
Tissue distribution of bisMSH-DTPA was determined in
DBA/2 mice. Tumours were induced by the intradermal or
intraperitoneal injection of 2-3 x 105 Cloudman S91 mela-
noma cells suspended in 0.1 ml of physiological saline. After
development for 18-21 days, the intradermal tumours were
between 3 and 7 mm in diameter.
BisMSH-DTPA-"'In complex was prepared as described
above by mixing 4 nmol peptide and 3.7 MBq carrier-free
"'In in 0.5 ml citrate buffer. After 60min the solution was
diluted to 2.5 ml with physiological saline and each mouse
was given 0.1 ml by intraperitoneal injection. The mice were
housed separately after injection to minimise urine con-
tamination of the skin. Animals were killed at intervals and
the tissues dissected and weighed. Radioactivity was deter-
mined with a Packard Multi-Prias 4 gamma counter, using a
window of 50-500 KeV. Results were corrected for radio-
active decay and expressed as percentages of the injected dose
per gram of tissue (wet weight).
In some experiments, mice bearing intradermal or intra-
peritoneal tumours were injected with bisMSH-DTPA-"'In
prepared as described above, but the solution also contained
a 200-fold molar excess of MSH. These mice, together with
their controls (bisMSH-DTPA-"'In only), were killed after
24 h and the tissues processed as above. The ratios of radio-
activity per gram of tissue to radioactivity per gram of whole
blood were calculated. Inhibition of uptake of radioactivity
was calculated by dividing the tissue/blood ratio in the
presence of competing MSH by the tissue/blood ratio in the
control.
Results
Stability ofthe bisMSH-DTPA-"'In complex
Thin layer chromatography in both solvent systems showed
that when the mixture ofbisMSH-DTPA and "'In was main-
tained at 37°C, the "'In had become completely bound to the
chelator-peptide within 15 min of mixing. The rate of chela-
tion was temperature dependent: at 20°C, 60 min were need-
ed for complete chelation, whilst at 4°C the time required
was 5 h. Incubation of bisMSH-DTPA-"'In in phosphate
buffered saline at pH values of 6.0, 7.4 and 8.4 resulted in no
detectable dissociation during 24 h. When the complex was
incubated with phosphate buffered saline, pH 6, containing
50% human plasma, no dissociation was detectable after 5 h
and 92% of the radioactivity remained bound to the peptide
after 24 h.
Measurement ofhormonal activity
Both MSH and bisMSH-DTPA showed maximal activity in
the tyrosinase assay at a concentration of 1 x 10-7 M (Figure
2), at which point the level of enzyme had been elevated to
4-4.5 times that in the melanotropin-free controls. At none
of the concentrations were the activities of MSH and
bisMSH-DTPA significantly different from each other. The
mean concentrations required for half maximal activity
(ECm), derived from the pooled data from Figure 2 by a
standard curve-fitting routine (Sigmaplot) were 2.81 nM for
MSH and 2.93 nM for bisMSH-DTPA.
Tissue distribution ofbisMSH-DTPA-"'In in vivo
Following the intraperitoneal injection of bisMSH-DTPA-
"'In into mice bearing Cloudman S91 melanomas, radio-
activity in tumour tissue rose to a maximum of 2.70 ± 0.24%
(n = 21) of the injected dose/g tissue at 24 h, and subse-
quently fell to 1.92 ± 0.21% (n = 8) at 48 h (Figure 3). Blood
levels in contrast fell rapidly after injection and by 24 h had
reached 0.33 ± 0.05% (n = 21) of the injected dose per g
whole blood. At 24 h, the mean tumour/blood ratio was 8.2
and at 48 h, 8.3. Elimination from the blood appeared to be
exponential with a half-life of 11 h.
At 24 h, all the tissues examined, apart from liver and
kidney, showed significantly lower uptakes of radioactivity
than tumour (P<0.001 in each case) (Figure 4). The lowest
uptake was seen in brain (0.034 ± 0.006% injected dose per g
tissue), followed by eye (0.20 ± 0.04%), heart (0.25 ± 0.03%),
skeletal muscle (0.33 ± 0.06%), lung (0.40 ± 0.06%), skin
(0.61 ± 0.04%) and spleen (1.13 ± 0.10%). The correspond-
ing mean tumour/tissue ratios for these tissues were brain 80,
eye 14, heart 11, skeletal muscle 8.1, lung 6.8, skin 4.4 and
spleen 2.4. The uptake by the liver was not significantly
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Figure 2 Effect of MSH (0) and bisMSH-DTPA (E) on tyro-
sinase activity in Cloudman S91 melanoma cells. Results are
expressed as the ratio of tritiated water produced per cell in
melanotropin treated cultures over the controls and are given as
the means±s.e.m. (n = 6 independent determinations).
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Figure 3 Radioactivity in tumour (0) and blood (0) of DBA/2
mice with Cloudman S91 melanoma following the injection of
bisMSH-DTPA-"'In (see text for details). Results are expressed
as percentages of the original dose per g tissue ± s.e.m. (n = 6 at
2 h, 22 at 4 and 24 h, 8 at 48 h and 4 at 96 h).
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Figure 4 Radioactivity in tissues of DBA/2 mice 24 h after
injection of bisMSH-DTPA-"'In (see text for details). Results are
expressed as percentages of the original dose per g tissue± s.e.m.,
n = 22. Hatched bar = tumour. *Results significantly lower than
tumour (P<0.001).
different from tumour, whereas kidney uptake was signi-
ficantly higher (P<0.001). Monitoring of tissue levels for
48 h and 96 h showed some increase in liver, spleen and lung.
Skin and kidney levels remained constant whereas brain, eye
and muscle levels continued to fall.
Addition of a 200-fold molar excess of MSH to the bis
MSH-DTPA-"'IIn complex reduced uptake by about half in
both intradermal and intraperitoneal tumours, whereas uptakes
by the liver and kidney were unaffected (Figure 5). Similarly,
uptakes by the spleen, lung, heart, brain, eye and skin were not
significantly reduced by the presence of competing MSH.
Discussion
The use of labelled hormone molecules to study receptor
dynamics and processing is a well-established technique in
vitro (Shimizu & Kawashima, 1989; Solca et al., 1989). In the
present paper, we show that these specific interactions can be
utilised in vivo to direct a radiochemical labelled derivative of
the hormone MSH to cells bearing the appropriate receptor.
The radioactivity associated with tumour tissue was reduced
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Figure 5 Inhibition ofuptake ofradioactivity in tissues ofDBA/
2 mice by a 200-fold molar excess of MSH (see text for details).
Results are expressed as percentages of the control (bisMSH-
DTPA-"'In only) tissue/blood ratios±s.e.m., n=5. Hatched
bars= tumour. Tumour IP=intraperitoneal tumour. Tumour
ID = intradermal tumour. Results significantly reduced relative to
their controls: a, P<0.02; b, P<0.05.
by about 50% in the presence of excess MSH suggesting that
about half had become associated with the cells via a recep-
tor mediated mechanism. Very little uptake was evident in
the brain which is known to contain MSH receptors (Ravid
et al., 1986). Whilst these experiments do not exclude the
possibility of specific uptake in small areas of brain bearing
MSH receptors, it was noteworthy that the radioactivity
which was taken up was not reduced significantly in the
presence of excess MSH. These results may suggest that
bisMSH-DTPA is unable to cross the blood-brain barrier.
The ratios of radioactivity in the tumour to that in other
tissues suggest that it would be possible to image melanomas
against a wide variety of background tissues, although the
identification of liver or kidney metastases would probably
require the use of a suitable subtraction technique.
The use of bisMSH-DTPA for the targeting of therapeutic
isotopes to melanomas would, however, be precluded by the
high levels of liver and kidney uptake. In rodents, neither
kidney nor liver appear to contain receptors for MSH (Tatro
& Reichlin, 1987) and hence the uptake we observe is
almost certainly non-specific. This supposition is supported
in our experiments by the inability of excess MSH to com-
pete with uptake of radioactivity in these organs (Figure 5).
The high kidney activity is, in part, a function of the rapid
rate of elimination from the blood, but the persistence of
radioactivity at this site, even at 96 h when 85% of the initial
radioactivity has been cleared from the blood, suggests an
accumulation a breakdown product of the peptide or an
inorganic indium colloid. The high levels of endopeptidase
activity in the kidney (Stephenson & Kenny, 1988) would
probably preclude the accumulation of intact peptide. The
liver activity may reflect accumulation of indium following
transfer from the DTPA complex to transferrin or the forma-
tion of colloidal hydroxide (Moerlein & Welch, 1981).
Unsubstituted DTPA forms an octadentate ligand with
indium (Maecke et al., 1989) and substitution of two of the
carboxylic acid groups of DTPA may well reduce the long-
term stability of the complex in vivo. This problem has been
3.0
2.0
K_
0.
I
'r,
01
b-
a3
UL)
0
10
.i
0
._
-o 0
'-I
h.._ 0
0
G)
U)
0
U
O_)
11922 D.R. BARD et al.
seen with similar chelators, but can be overcome by the use
of macrocylic complexing agents such as 1,4,7,10-tetraaza-
cyclododecane-N,N',N",N"'-tetraacetic acid which form com-
plexes which are much more stable in plasma (Moi et al.,
1988).
The half-life of MSH in rodent blood has been reported to
be around 30 min (Wilson & Morgan, 1980), whereas we
have shown that the physiological half-life of radioactivity in
the blood was 11 h. In the later stages of the present exper-
iments, therefore, it is probable that most of the radioactivity
was in a form other than intact bisMSH-DTPA-1"In. The
relatively high levels of bisMSH-DTPA-Il'In injected, how-
ever, would have ensured that the concentration in the blood
remained significantly higher than that of naturally circu-
lating MSH for several hours. The maximum levels of
bisMSH-DTPA in the blood following injection would have
been about 0.8p1gml-, and, assuming that bisMSH-DTPA
was broken down at approximately the same rate as the
native hormone, the time taken to reach a concentration
equivalent to the naturally circulating hormone (30pgml-';
Eberle, 1988) would be between 7 h and 8 h. The use of
analogues of MSH with greater resistance to proteolysis
(Sawyer et al., 1980; Castrucci et al., 1984) may enable lower
doses to be used and higher tumour/tissue ratios to be
obtained.
It can be anticipated that a clinically useful targeting agent
would need to be used on several occasions in the manage-
ment of melanoma and low molecular weight carriers based
on naturally occurring hormones may avoid the problem of
immune elimination seen with monoclonal antibody targeting
(Larson et al., 1983; Schroff et al., 1985). BisMSH-DTPA is
currently in clinical trial as an imaging agent and the
development of derivatives based on other analogues of
MSH and more stable chelators is in progress.
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